Jeffery A.

Hobden, PhD
Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
General Outline for Antibiotics (a good study guide)
I. Chemistry (structure) covered in MIP
II. Effect on Microbes covered in MIP, briefly reviewed here
A. spectrum of coverage
B. mechanism(s) of action
C. mechanism(s) of resistance
III. Pharmacology of Antibiotic Class mostly new information
A. Absorbance
B. Fate after absorption
C. Excretion
IV. Pharmacology of Select Agents within Class mostly new information
V. Therapeutic Uses somewhat new information
VI. Toxicity/Contraindications- mostly new information
A. common (greater than 10%)
B. uncommon (1-9%)
C. rare (less than 1%)
Sulfonamides
I. Chemistry
A. sulfonamide generic term for derivatives of para-aminobenzenesulfonamide
B. analogues of para-aminobenzoic acid
C. sodium salts are water soluble
II. Effect on Microbes
A. spectrum of coverage broad (both G+ and G-)
B. mechanism of action
1. competitive inhibitors of dihydropteroate synthase
2. bacteria cannot synthesize their own folic acid
3. bacteriostatic in most tissues, can be cidal in urine
C. mechanism(s) of resistance
1. lower affinity for dihydropteroate synthase
2. decreased permeability or active efflux
3. found a new pathway to make folic acid
III. Pharmacology of the Sulfonamides
A. Absorbance
1. 70-100% of an oral dose is absorbed from the gastrointestinal tract
(mostly from small intestine, but also from stomach)
2. absorption from other sites (vagina, abraded skin, respiratory tract) is
variable and unreliable but may be enough to trigger adverse
reactions
B. Fate after absorption
1. binds to serum albumin to varying degrees
2. distributed throughout all tissues of the body
3. readily cross the placenta and reach fetal circulation

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
4. acetylation occurs in the liver to varying degrees (acetylated
sulfonamides loose antibacterial activity but can still elicit toxic
reactions)
C. Excretion
1. eliminated mostly by the kidneys into the urine, partially unchanged,
partially metabolized
2. some drugs become insoluble in acid urine and may precipitate
IV. Pharmacology of Select Sulfonamides
A. rapidly absorbed and eliminated sulfonamides (sulfisoxazole,
sulfamethoxazole, sulfadiazine)
1. bind extensively to plasma proteins
2. most of the drug excreted into urine after a single oral dose
3. concentrations in urine high enough to bactericidal
4. sulfamethoxazole combined with trimethoprim (Bactrim) is widely
used to treat UTI (see below), respiratory tract infections,
gastrointestinal
infections, and pneumocystis infections
B. poorly absorbed sulfonamides (sulfasalazine)
1. poorly absorbed in GI tract
2. used to treat ulcerative colitis, irritable bowel syndrome
3. gut bacteria break down drug into sulfapyridine and 5-aminosalicylate
4. toxicity due to sulfapyridine, therapeutic action due to 5aminosalicylate
C. sulfonamides for topical use (sulfacetamide and silver sulfadiazine)
1. sulfacetamide is used to treat ophthalmic infections
a) very high aqueous concentrations are not irritating (pH 7.4)
b) very good penetration into ocular tissue
2. silver sulfadiazine is used to prevent burn wound infections
D. long acting sulfonamides (sulfadoxine)
1. has a serum half life of 7-9 DAYS!
2. combined with pyrimethamine to prevent and treat malaria
V. Therapeutic Uses
A. urinary tract infections
1. most uropathogens are resistant to sulfonamides alone
2. sulfamethoxazole combined with trimethoprim is effective
B. nocardiosis
1. trimethoprim-sulfamethoxazole is drug of choice
2. sulfisoxazole and sulfadiazine are also effective
C. toxoplasmosis pyrimethamine plus sulfadiazine
VI. Toxicity/Contraindications
A. urinary tract (common to uncommon)
1. sulfamethoxazole and sulfadiazine can crystallize in acid urine or in
dehydrated patients causing urinary obstructions
2. can prevent by alkalizing urine with sodium bicarbonate or increasing
hydration

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
B. hematopoietic system (rare to extremely rare)
1. acute hemolytic anemia associated with deficiency of glucose-6phosphate dehydrogenase activity in RBC
2. agranulocytosis
3. aplastic anemia
C. hypersensitivity reactions (common to uncommon)
1. skin and mucous membrane manifestations (rashes)
a) Stevens-Johnson Syndrome (SJS)
b) toxic epidermal necrolysis (TEN)
2. serum sickness
3. focal or diffuse necrosis of liver (rare)
D. miscellaneous reactions (common)
1. nausea, anorexia, and vomiting
2. kernicterus (newborns)
a) displacement of bilirubin from plasma albumin
b) bilirubin deposits in brain, causing an encephalopathy
c) this is why sulfonamides are not given to pregnant or
lactating women!
E. drug interactions - sulfonamides potentiate effects of oral anticoagulants,
sulfonylurea hypoglycemics, and hydrantoin anticonvuslants
Quinolones
I. Chemistry
A. first quinolone, naladixic acid, was a byproduct of chloroquine synthesis (an
antimalarial drug)
B. current drugs are fluorinated 4-quinolones
II. Effect on Microbes
A. spectrum of coverage
1. broad (both G+ and G-, but some fluoroquinolones have better
coverage against G+ than others)
2. works well against intracellular pathogens
3. newer fluoroquinolones work against anaerobes
B. mechanism of action
1. targets are DNA gyrase (for G-) and topoisomerase IV (for G+)
2. inhibition of gyrase prevents negative supercoiling in replicating DNA
3. inhibition of topoisomerase IV prevents separation of catenated DNA
C. mechanism of resistance
1. mutations in chromosomal genes for gyrase and topoisomerase IV that
result in proteins with less binding potential
2. active transport out of cell with efflux pumps
III. Pharmacology of Quinolones
A. absorbance
1. well absorbed after oral administration with peak serum levels reached
within 1 to 3 hours

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
2. food does not impair absorption but it might delay time to peak serum
concentrations
B. Fate after absorption
1. bioavailability of fluoroquinolones is better than 50% for all agents
(95% for some)
2. volume of distribution is high in urine, kidney, lung, prostate, stool,
blood, and within macrophages and neutrophils
3. concentrations in CSF, bone, and prostatic fluid are less than serum
levels
C. Excretion
1. most are cleared by the kidney so adjust dosage for renal patients
2. exceptions are pefloxacin and moxifloxacin which are metabolized by
the liver; do not use in patients with hepatic failure
3. none of the fluoroquinolones is removed by peritoneal dialysis or
hemodialysis
4. ciprofloxacin, ofloxacin, and pefloxacin are excreted in breast milk
IV. Pharmacology of Select Quinolones
A. norfloxacin relatively low serum levels are obtained, but achieves good
levels in urine
B. pefloxacin and moxifloxacin are metabolized by liver unlike other agents
V. Therapeutic Uses
A. urinary tract infections
1. naladixic acid is useful if the uropathogen is susceptible (most these
days are not), but other fluoroquinolones like ciprofloxacin are just
as
effective
2. clinical trials show that fluoroquinolones more efficacious than
trimethoprim-sulfamethoxazole
B. Prostatitis
C. STDs
1. cures Chlamydia, and chancroid (Haemophilus. ducreyi), but not
syphilis (Treponema pallidum)
2. N. gonorrheae has become resistant to ofloxacin and ciprofloxacin so
fluoroquinolones are no longer recommended as treatment options
D. gastrointestinal and abdominal infections
1. fluoroquinolones work well in treating travelers diarrhea, shigellosis,
and typhoid fever (salmonellosis)
2. can induce shiga-like toxin expression in E. coli (this is bad because
this toxin is responsible for hemolytic uremic syndrome)
E. respiratory tract infections
1. older fluoroquinolones like ciprofloxacin, ofloxacin and norfloxacin
have poor activity against Streptococcus pneumoniae and anerobes
2. newer agents like gatifloxacin and moxifloxacin work much better
against S. pneumoniae and are comparable to beta-lactam drugs

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
3. all work well against atypical organisms causing community-acquired
pneumonia (Mycoplasma and Chlamydia pneumoniae)
F. bone, joint, and soft tissue infections
1. because they can be given orally and bugs are generally susceptible to
fluoroquinolones, they are ideal for treating chronic osteomylitis or
joint
infections
2. resistance to some agents has developed in Staphylococcus aureus,
Pseudomonas aeruginosa, and Serratia marcesens
3. because they cover a broad range of microorganisms, fluoroquinolones
are useful in treating polymicrobial infections of soft tissue
(diabetic foot,
venous ulcers)
G. miscellaneous infections
1. ciprofloxacin useful for anthrax exposure and treating tularemia
2. mixed with other drugs (aminoglycosides or beta-lactams), useful for
treating atypical mycobacterial infections or prophylaxis for
neutropenic
cancer patients
VI. Toxicity/Contraindications
A. nausea, vomiting and abdominal discomfort (common)
B. diarrhea and antibiotic-associated colitis (uncommon to rare)
C. CNS side effects
1. mild headache and dizziness (common to rare)
2. hallucinations, delirium and seizures (rare), usually in patients also
taking theophylline or an NSAID
D. arthropathy in immature animals (common)
1. quinolones not given to children usually
2. if benefit outweighs risk, then OK
E. leucopenia, eosinophila, heart arythmias (rare)
Penicillins
I. Chemistry
A. basic structure of all penicillins consists of a thiozolidine ring connected to a
beta-lactam ring attached to a side chain (R)
B. the side chain determines antibacterial and pharmacological properties
C. Penicillium notatum produces the only naturally occurring penicillin in use
(penicillin G or benzylpenicillin); dosage and potency based on the international
unit (IU). 1 IU of PenG activity = 0.6 micrograms of pure crystalline PenG
D. P. chrysogenum produces 6-aminopenicillanic acid, the raw material for
semisynthetic penicillins (chemists add the R groups); dosage and potency based
on weight
II. Effects on Microbes
A. spectrum of coverage
1. depends on chemical structure (R groups)
2. some work only on G+, some broad spectrum

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
3. some effective against anaerobes and intracellular pathogens
B. mechanism of action
1. all are bactericidal
2. inhibit transpeptidases which are essential for peptidoglycan synthesis
3. cell lyses in right osmotic environment
C. mechanisms of resistance
1. alter the affinity of transpeptidases for binding to penicillin
2. enzymatically cleave the beta-lactam ring and prevent binding to
transpeptidase
3. active transport out of cell (efflux pumps)
4. poor penetration into cell (intrinsic resistance)
III. Pharmacology of Penicillins
A. absorbance- administered orally, intramuscularly, or intravenously
B. fate after absorption
1. after oral dose, widely distributed in tissues and secretions
2. do not penetrate living cells, and poor penetration into prostatic fluid,
brain tissue, or intraocular fluid
3. food interferes with absorption
C. excretion
1. rapid elimination through kidney urine concentrations high
2. found in breast milk
IV. Pharmacology of Select Penicillins
A. the naturals - penicillin G and penicillin V
1. antimicrobial activity
a) both share antimicrobial spectra for aerobic G+ organisms but
penicillin G is more acive against Neisseria sp. and
anaerobes
b) 90% of staphylococci are resistant, most gonococci are too
2. absorption
a) only one-third of oral penicillin G is rapidly absorbed from
intestinal tract, rest is destroyed by stomach acid
b) when given parenterally, penicillin G peaks in serum in 15 to 30
minutes, then rapidly declines because half life is 30 minutes
c) to slow down the clearance of penicillin G from the body, it is
sometimes combined with probenecid (blocks renal
secretion),
procaine (adjuvant-like effect, slowly releases
agent) or benzathine
(same as procaine)
d) oral penicillin V reaches 2 to 5 times serum concentration than
oral penicillin G because of its greater resistance to
stomach acid
3. fate after absorption
a) 60% of penicillin G is bound to albumin
b) significant amounts are found in liver, bile, kidney, semen, joint
fluid, lymph, and intestine

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
c) penetration into CSF is poor unless there is inflammation
4. excretion
a) eliminated rapidly (i.e., 30 minutes) from the body by kidneys
b) in neonates and infants, clearance is much less because renal
function hasnt been fully established
c) in patients with renal failure, liver will inactivate penicillin G at
the rate of 10% per hour
5. therapeutic uses
a) Streptococcus pneumoniae infections (pneumonia and
meningitis
b) Streptococcus pyogenes infections (pharyngitis, Scarlet Fever,
toxic shock, necrotizing fascititis, arthritis, meningitis, etc);
also
given prophylactically
c) viridans streptococcal endocarditis (also given prophylactically)
d) anaerobes except Bacteroides fragilis group
e) meningococcal infections
f) syphilis and other diseases caused by spirochetes
B. the isoxazolyl penicillins oxacillin, cloxacillin, dicloxacillin, nafcillin
1. antimicrobial activity
a) these drugs were made to resist staphylococcal penicillinases
b) activity against staph not guaranteed with rise of MRSA
2. absorption
a) oxacillin, cloxacillin, and dicloxacillin are pharmacologically
similar stable in gastric acid and readily absorbed after
oral
administration; can also be administered parenterally for
serious
cases of staphylococcal disease; food interferes with
absorption
b) nafcillin is inactivated by acid pH so its given parenterally
3. fate after absorption
a) all bind plasma proteins 90 95%
b) distribution similar to penicillin G
4. excretion
a) rapidly excreted by kidneys
b) significant hepatic elimination into bile
5. therapeutic uses
a) community acquired MSSA infections
b) not effective against enterococci or Listeria
C. the aminopenicillins ampicillin and amoxicillin
1. antimicrobial activity
a) broad spectrum
b) do not work against beta-lactamase producers (i.e.
Pseudomonas, Proteus, Klebsiella, etc)
c) beta-lactamase inhibitors (clavulanate, sulbactam) extend the
spectrum somewhat

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
2. absorption
a) both are acid resistant but more amoxicillin is absorbed by the
intestinal tract than ampicillin after an oral dosage
b) food interferes with absorption of ampicillin but not amoxicillin
3. fate after absorption 20% bound to plasma proteins
4. excretion
a) both are excreted from the kidneys
b) significant amounts of ampicillin found in feces
5. therapeutic uses
a) upper respiratory tract infections
b) otitis media
c) uncomplicated urinary tract infections
d) acute bacterial meningitis in children
e) typhoid fever
D. a carboxypenicillin (ticarcillin) and a ureidopenicillin (piperacillin)
1. antimicrobial activity
a) ticarcillin is an anti-pseudomonal drug
b) piperacillin plus tazobactam (a beta-lactamase inhibitor) has the
broadest spectrum of all penicillins
2. absorption given parenterally
3. fate after absorption same as other penicillins
4. excretion kidneys
5. therapeutic uses
a) for immunocompromised patients with serious G- infections
b) bacteremias, UTI, pneumonias
V. Therapeutic Uses (see above, depends on chemistry)
VI. Toxicity/Contraindications
A. hypersensitivity reactions (uncommon)
1. in order of decreasing frequency: maculopapular rash, urticarial rash,
fever, bronchospasm, vasculitis, serum sickness, exfoliative
dermatitis,
Stevens-Johnson syndrome, anaphylaxis
2. agents act as haptens when bound to serum proteins
3. rashes will disappear when drug is withdrawn, can use antihistamines or
glucocorticoids
4. for patients with allergies, use a different drug or try to desensitize
B. other adverse reactions
1. pain and sterile inflammatory reactions at sites of IM injections
2. large doses (>20 million IU/day) given to patients with renal failure can
cause lethargy, confusion, twitching, and seizures (although these very
same symptoms sometimes occur in sophomore medical students
who
cram before a pharmacology exam)
3. dizziness, tinnitus, headache, hallucinations are side effects sometimes
seen with penicillin G procaine injections for venereal disease due
to
sudden release of procaine

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
4. pseudomembranous colitis due to Clostridium difficle overgrowth

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
The Cephalosporins
I. Chemistry
A. the base molecule is 7-aminocephalosporanic acid, produced by
Cephalosporium acremonium (a Sardinian sewer mold)
B. as with their beta-lactam cousins, the penicillins, adding side chains
determines the antibacterial spectrum and pharmacological properties
II. Effect on Microbes similar to penicillins
III. Pharmacology of Cephalosporins essentially the same as penicillins
IV. Pharmacology of Select Cephalosporins
A. first generation cefazolin, cephalexin, cephadroxil
1. antimicrobial activity
a) excellent against susceptible staph and strep
b) modest activity against G2. absorption
a) cefazolin is only given parenterally
b) cephalexin and cephadroxil can be given orally and parenterally
3. fate after absorption - more than 50% bound to plasma proteins
4. excretion excreted by kidneys un-metabolized
5. therapeutic uses -skin and soft tissue infections (staph and strep)
B. second generation cefaclor, cefuroxime, cefprozil
1. antimicrobial activity
a) modest activity against G+
b) increased activity over first generation for Gc) works against anaerobes (Bacteroides)
2. absorption - cefaclor and cefprozil can be given orally
3. fate after absorption essentially same as first generation
4. excretion essentially same as first generation
5. therapeutic uses
a) respiratory tract infections
b) intra-abdominal infections
c) pelvic inflammatory disease
d) diabetic foot ulcers
C. third generation cefotaxime, ceftriaxone, cefoperazone, cefpodoxime
1. antimicrobial activity
a) broad spectrum nuke-em antibiotics
b) drugs of choice for serious infections, including those caused
by Klebsiella, Enterobacter, Serratia, and Pseudomonas
c) lack activity against Listeria monocytogenes and penicillinresistant pneumococci (agents of bacterial meningitis)
2. absorption cefpodoxime given orally
3. fate after absorption - cefotaxime is deacetylated to a compound with
lesser activity
4. excretion
a) most excreted by kidney

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
b) ceftriaxzone is secreted by kidney and into bile
5. therapeutic uses
a) bacterial meningitis (with two exceptions)
b) Lyme disease
c) life-threatening G- sepsis
D. fourth generation cefepime
1. antimicrobial activity same as third generation but resists more betalactamases
2. absorption parenterally only
3. fate after absorption excellent penetration into CSF
4. excretion 100% by kidneys
5. therapeutic use nosocomial infections
V. Therapeutic Uses (see above, depends on chemistry)
VI. Toxicity/Contraindications
A. hypersensitivity reactions (uncommon)
1. essentially the same as for the penicillins
2. cross-reactivity is possible
B. nephrotoxicity (rare)
The Carbapenems
I. Chemistry
A. beta-lactam ring is fused to a five member ring system
B. unlike penicillins, 5 member ring is unsaturated and has a C instead of an S
II. Effect on Microbes similar to penicillins
III. Pharmacology of Carbapenems essentially the same as penicillins
IV. Pharmacology of Select Carbapenems
A. imipenem
1. antimicrobial activity broad spectrum
a) works well against anaerobes
b) works well against Pseudomonas
2. absorption
a) parental administration only
b) must be combined with cilastatin, a compound which
inactivates a kidney dipeptidase that would otherwise
inactivate
imipenem
3. fate after absorption similar to other beta-lactams
4. excretion
a) excreted by kidneys (70% active drug in urine)
b) monitor drug concentrations in patients with renal failure
5. therapeutic use just about any infection you can think of, including
nosocomial infections with bacteria resistant to other beta-lactams
B. meropenem and ertapenem - same as imipenem but do not require cilastatin
C. aztrenam (a monobactam)
1. antimicrobial activity

Jeffery A. Hobden, PhD

Pharmacology Antimicrobial Agents
Chapters 43-44, Goodman & Gilson
March 2009
a) only active against G- bacteria, including Pseudomonas
b) not effective against anaerobes
2. absorption parental administration only
3. fate after absorption not metabolized
4. excretion kidneys (watch for toxicity in renal patients)
5. therapeutic uses useful for treating G- infections that would normally
be treated with a beta-lactam (*does not cross-react with other
betalactams and is safe to use in patients with penicillin allergies)
V. Therapeutic Uses (see above)
VI. Toxicity/Contraindications
A. nausea and vomiting (common)
B. hypersensitivity reactions (uncommon)
1. essentially the same as for the penicillins
2. cross-reactivity is possible
3. exception to the rule is aztrenam